A clinical-stage maternal health company betting that a small cervical cuff can buy a pregnancy more time - and that obstetrics has waited far too long for someone to try.
Somewhere in a research hospital in 2026, a woman roughly 24 weeks pregnant is told her water has broken far too early. For most of medical history, the next sentence is some version of "we wait, and we hope." Novocuff exists to add a third option to that conversation.
The company is a clinical-stage maternal health medical device firm in Mountain View, California, with around eleven people and one stubbornly focused idea. It is a company in residence at Fogarty Innovation, the medtech incubator that has turned more clinical hunches into approved devices than almost anywhere on earth. In September 2025 it cleared the regulatory bar it had been building toward for years: FDA approval of its Investigational Device Exemption, the green light for a full pivotal trial.
Novocuff is not a platform, not a pipeline, not a suite. It is one device for two conditions that the delivery room has long treated as a coin toss. That narrowness is the whole strategy.
Two complications sit at the center of Novocuff's work. The first is preterm prelabor rupture of membranes, or PPROM - when the amniotic sac breaks before labor and before term. It affects somewhere between 2 and 4 percent of U.S. pregnancies, and it nearly always ends in preterm birth. The second is cervical shortening, or insufficiency, where the cervix opens too soon and quietly raises the risk of loss.
Preterm birth is the leading cause of newborn death worldwide. You would expect, given the stakes, a crowded field of solutions. Instead the standard responses have barely changed in decades: bed rest, a cervical stitch, a pessary ring, progesterone, and a great deal of waiting. As one of the trial's principal investigators put it, this is a condition with "a dearth of innovation."
The cruel arithmetic of PPROM is simple: every extra day a baby stays in the womb improves the odds. The problem is that the tools to add those days have been blunt. Novocuff looked at that gap and asked an almost impertinent question - what if you could just hold things closed?
Novocuff was founded in 2021 by Amelia Degenkolb and Donald Lee. Degenkolb leads as CEO; Lee runs operations as COO. Their bet was not that the problem was easy - it plainly is not - but that the solution did not need to be complicated to be useful.
It is a slightly unfashionable position. The temptation in medtech is to build something dazzling: sensors, software, a dashboard. Novocuff went the other way. The Cervical Control System is designed to do one mechanical thing well - stabilize and close the cervix, retain amniotic fluid, maintain cervical length, and extend gestation. The simplicity is not a shortcut. It is the argument.
Leads strategy, fundraising and clinical development. The public voice of the company's mission to change standard pregnancy care.
Runs operations and execution as Novocuff scales from a prototype idea toward a multi-center pivotal trial.
The device, still investigational and limited by U.S. law to research use, is built around a single job. It stabilizes and closes the cervix, helps retain amniotic fluid, and works to maintain cervical length - all in service of extending a pregnancy that would otherwise end early. In the RETAIN study it is being evaluated in singleton pregnancies complicated by PPROM as early as 24 weeks.
There is a tidy irony in the trial's name. RETAIN is exactly what the device is meant to do - retain the fluid, retain the pregnancy, retain the days that matter most. The acronym practically wrote itself.
PPROM and cervical shortening - two leading drivers of preterm birth.
Mechanically stabilizes and closes the cervix to keep amniotic fluid in.
Extend gestation, because every additional day improves newborn outcomes.
Investigational; under evaluation in the FDA-cleared RETAIN pivotal trial.
Conviction is cheap; an oversubscribed round is not. In July 2024, Novocuff closed a $26 million Series A - oversubscribed, which in venture terms means more people wanted in than there was room for. AXA IM Alts led with a $14 million check through its global healthcare private equity strategy. Around it gathered Laerdal Million Lives Fund, Laborie, RH Capital, Avestria Ventures and March of Dimes.
That last name matters. March of Dimes began in 1938 as a campaign against polio and long ago turned its full attention to mothers and babies. When a nearly century-old maternal health institution writes a check, it is a particular kind of endorsement.
The clinical credibility is just as deliberate. The RETAIN trial is co-led by Dr. Lisa Zuckerwise of the University of Virginia School of Medicine and Dr. Dwight Rouse of Women's & Infants Hospital of Rhode Island and Brown University - two maternal-fetal medicine names you do not put on a study unless you mean it.
Novocuff frames its purpose plainly: support moms and babies, and improve outcomes for women and newborns affected by PPROM and cervical shortening. There is no grander mission statement, and it does not need one. In a field where the standard of care has been waiting and hoping, the ambition to add a real option is large enough.
What makes the company distinctive is its refusal to over-engineer. The pitch is almost confrontationally simple - a complex problem, a simple device, and the discipline to prove it with a proper randomized trial rather than a press release. The hard part was never imagining the device. It was earning the right to test it on the patients who need it.
Return to the hospital room. The woman is still 24 weeks pregnant, her water still broken far too early. The difference Novocuff is chasing is the sentence that comes after the bad news. Not "we wait, and we hope," but "there is something we can try, and here is the evidence."
That sentence does not exist yet. It depends on a trial of up to 272 participants finishing, on the data holding, on the FDA agreeing. None of that is guaranteed, and Novocuff is careful to say so - the device remains investigational. But for the first time in a long while, there is a credible, well-funded, clinically serious attempt to write it.
A small team. A small device. A problem that has stayed enormous precisely because no one made it smaller. If Novocuff is right, the cuff that fits on a business card changes what the delivery room can say to the people who need it most. That is the whole bet, and they have put $28 million and a pivotal trial behind it.
Profile compiled from public sources. The Novocuff Cervical Control System is investigational and limited by U.S. law to research use. Figures are approximate where noted.